Perinatal HIV-1 transmission -: Interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort

被引:201
|
作者
Mandelbrot, L
Le Chenadec, J
Berrebi, A
Bongain, M
Bénifla, JL
Delfraissy, JF
Blanche, S
Mayaux, MJ
机构
[1] Hop Cochin Port Royal, Serv Gynecol Obstet 1, F-75014 Paris, France
[2] INSERM, U149, Paris, France
[3] INSERM, U292, Le Kremlin Bicetre, France
[4] Hop La Grave, Serv Gynecol Obstet, Toulouse, France
[5] Hop Archet 2, Serv Gynecol Obstet, Nice, France
[6] Hop Bichat Claude Bernard, Serv Gynecol Obstet, F-75877 Paris, France
[7] Hop Kremlin Bicetre, Serv Med Interne, Le Kremlin Bicetre, France
[8] Hop Necker Enfants Malad, Serv Pediat, Paris, France
来源
关键词
D O I
10.1001/jama.280.1.55
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context.-It is unclear whether elective cesarean delivery may have a protective effect against the transmission of human immunodeficiency virus 1 (HIV-1). Objective.-To investigate whether mode of delivery has an impact on perinatal HIV-1 transmission in the presence of zidovudine prophylaxis. Design.-A prospective cohort study. Setting.-The 85 perinatal centers in the French Perinatal Cohort, from 1985 to 1996. Patients.-A total of 2834 singleton children born to mothers with HIV-1 infection. Main Outcome Measure.-Human immunodeficiency virus 1 infection of the infant. Results.-No zidovudine was used in 1917 pregnancies and zidovudine prophylaxis was used in 902 pregnancies. Cesarean deliveries were performed in 10.9% on an emergent basis and in 8.3% electively, prior to labor or membrane rupture. In 1917 mothers who did not receive zidovudine, of 1877 with information on mode of delivery, 17.2% transmitted HIV-1 to their child. Risk factors statistically significantly associated with transmission were maternal p24 antigenemia, cervicovaginal infections during pregnancy, amniotic fluid color, and rupture of membranes 4 hours or more before delivery. Mode of delivery was not related to transmission. in 902 mothers receiving zidovudine, transmission was 6.4% in 872 with information on mode of delivery, and elective cesarean delivery (n = 133) was associated with a lower transmission rate than emergent cesarean or vaginal delivery (0.8%, 11.4%, and 6.6%, respectively; P=.002). In a multivariate analysis of all mother-child pairs, including obstetrical risk factors, maternal p24 antigenemia, and zidovudine prophylaxis, interaction between mode of delivery and zidovudine prophylaxis was significant (P=.007). In the multivariate analysis of pregnancies with zidovudine prophylaxis, factors related to transmission rate were maternal p24 antigenemia, amniotic fluid color, and mode of delivery. Adjusted odds ratios (95% confidence intervals) were 1.6 (0.7-3.6) for emergent cesarean delivery and 0.2 (0.0-0.9) for elective cesarean delivery (P =.04) in comparison with vaginal delivery. Conclusions.-We observed an interaction between zidovudine prophylaxis and elective cesarean delivery in decreasing transmission of HIV-1 from mother to child. This observation may have clinical implications for prevention.
引用
收藏
页码:55 / 60
页数:6
相关论文
共 50 条
  • [41] VARIATION IN ENV GENE SEQUENCE AND PERINATAL TRANSMISSION OF HIV-1
    ROUSSEAU, C
    LOUIE, L
    LEE, M
    JUST, J
    SHEPPARD, H
    ABRAMS, E
    STEIN, Z
    KING, MC
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 1995, : 243 - 243
  • [42] Predictors and impact of losses to follow-up in an HIV-1 perinatal transmission cohort in Malawi
    Ioannidis, JPA
    Taha, TE
    Kumwenda, N
    Broadhead, R
    Mtimavalye, L
    Miotti, P
    Yellin, F
    Contopoulos-Ioannidis, DG
    Biggar, RJ
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1999, 28 (04) : 769 - 775
  • [43] Perinatal HIV-1 transmission and intrauterine growth: A prospective cohort study in Butare, Rwanda.
    Bulterys, M
    Weng, S
    Chao, A
    Stidley, CA
    Dushimimana, A
    Mbarutso, E
    Saah, A
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 1998, 147 (11) : S33 - S33
  • [44] MATERNAL FACTORS ASSOCIATED WITH PERINATAL HIV-1 TRANSMISSION - THE FRENCH COHORT STUDY - 7 YEARS OF FOLLOW-UP OBSERVATION
    MAYAUX, MJ
    BLANCHE, S
    ROUZIOUX, C
    LECHENADEC, J
    CHAMBRIN, V
    FIRTION, G
    ALLEMON, MC
    VILMER, E
    VIGNERON, NC
    TRICOIRE, J
    GUILLOT, F
    COURPOTIN, C
    TARDIEU, M
    NOSEDA, G
    HURAUX, JM
    LEVINE, M
    DECREPY, A
    SIMON, F
    KRIVINE, A
    FRANCOUAL, C
    DIMARIA, L
    BURGARD, M
    GIRAULT, D
    STEPHAN, JL
    TERRIS, J
    VEBER, F
    MATHIEU, FP
    HERVE, F
    ALLISY, C
    DANDINE, M
    LABRUNE, P
    VIAL, M
    LACHASSINE, E
    FLOCH, C
    MAZY, F
    MEYER, F
    ROBIN, M
    TALON, P
    BERTEROTTIERE, D
    ROUSSET, MC
    WIPFF, P
    VINAS, A
    NARCY, P
    ARMENGAUD, D
    LEBLANC, A
    MAY, A
    DOUARD, D
    FLEURY, P
    BROUARD, J
    FREYMUTH, F
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 8 (02): : 188 - 194
  • [45] Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center
    Wiznia, AA
    Crane, M
    Lambert, G
    Sansary, J
    Harris, A
    Solomon, L
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (19): : 1504 - 1506
  • [46] Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine
    Hanson, IC
    Antonelli, TA
    Sperling, RS
    Oleske, JM
    Cooper, E
    Culnane, M
    Fowler, MG
    Kalish, LA
    Lee, SS
    McSherry, G
    Mofenson, L
    Shapiro, DE
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 20 (05): : 463 - 467
  • [47] Reducing the risk of perinatal HIV-1 transmission with zidovudine: Results and implications of AIDS Clinical Trials Group protocol 076
    Mofenson, LM
    [J]. ACTA PAEDIATRICA, 1997, 86 : 89 - 96
  • [48] A RISK-BENEFIT ASSESSMENT OF ZIDOVUDINE IN THE PREVENTION OF PERINATAL HIV TRANSMISSION
    NEWELL, ML
    GIBB, DM
    [J]. DRUG SAFETY, 1995, 12 (04) : 274 - 282
  • [49] Adequacy of prenatal care and prescription of zidovudine to prevent perinatal HIV transmission
    Lansky, A
    Jones, JL
    Burkham, S
    Reynolds, K
    Bohannon, B
    Bertolli, J
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (03): : 223 - 227
  • [50] Prevention of perinatal transmission of zidovudine- and nevirapine-resistant HIV
    Cha, Agnes
    Elsamadisi, Pansy
    Su, Christy Peggy
    Phipps, Emmet
    Birnbaum, Jeffrey M.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (07) : 451 - 455